Marker Therapeutics (MRKR) Shares Outstanding (Weighted Average) (2010 - 2026)

Marker Therapeutics (MRKR) has 17 years of Shares Outstanding (Weighted Average) data on file, last reported at $19.3 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $19.3 million, up 73.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.3 million (up 73.91% YoY), and the FY2025 annual result was $7.7 million, down 14.56% from the prior year.
• Shares Outstanding (Weighted Average) climbed to $19.3 million in Q1 2026 per MRKR's latest filing, from $7.7 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $19.3 million in Q1 2026 and troughed at $7.7 million in Q4 2025.
• A 5-year average of $9.9 million and a median of $8.8 million in 2023 frame the typical range for Shares Outstanding (Weighted Average).
• On a YoY basis, Shares Outstanding (Weighted Average) climbed as much as 321.13% in 2022 and fell as far as 89.96% in 2022.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $8.4 million in 2022, then climbed by 5.49% to $8.8 million in 2023, then increased by 1.94% to $9.0 million in 2024, then retreated by 14.56% to $7.7 million in 2025, then jumped by 151.73% to $19.3 million in 2026.
• Business Quant data shows MRKR's Shares Outstanding (Weighted Average) at $19.3 million in Q1 2026, $7.7 million in Q4 2025, and $14.0 million in Q3 2025.